Summary by Moomoo AI
Eli Lilly and Company reported a significant change in its executive team with the resignation of Anat Ashkenazi as the executive vice president and chief financial officer, effective June 5, 2024. Ashkenazi has decided to leave the pharmaceutical industry to pursue a different career path. Following her departure, Gordon Brooks, who has been with Eli Lilly for 29 years and currently serves as the group vice president, controller and corporate strategy, will take over as the interim chief financial officer starting July 15, 2024. Brooks has a diverse background within the company's finance organization, including roles as senior vice president, chief procurement officer, and general auditor. The company has confirmed that there are no familial or transactional relationships influencing Brooks' appointment. Ashkenazi will assist with the transition until the end of July 2024.